- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00392782
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
RATIONALE: Giving total-body irradiation and chemotherapy, such as fludarabine and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin and removing the T cells from the donor cells before transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well a donor stem cell transplant works in treating patients with myeloid cancer or other disease.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
OBJECTIVES:
Primary
- Determine the incidence of disease-free survival at 1 year in patients with acute or chronic myeloid leukemias undergoing T-cell-depleted hematopoietic stem cell transplantation from HLA-C mismatched, unrelated donors.
Secondary
- Determine the incidence of disease relapse at 1 year in patients treated with this regimen.
- Determine the incidence and severity of acute graft-vs-host disease (GVHD) at 100 days and chronic GVHD at 1 year in these patients.
- Determine the incidence of graft failure at day 100.
- Determine the transplant-related mortality of these patients at 1 year.
- Determine the overall survival of these patients at 1 year.
OUTLINE: This is a prospective, multicenter study. Patients are stratified according to killer-cell immunoglobulin-like receptors (KIR) epitope mismatch (yes [experimental] vs no [control]).
- Myeloablative preparative regimen: Patients undergo total body irradiation twice daily on days -10 and -9 and receive thiotepa intravenously (IV) over 4 hours on days -8 and -7, fludarabine phosphate IV over 30-60 minutes on days -7 to -3, and antithymocyte globulin IV over 4-6 hours on days -5 to -2.
- Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo filgrastim (G-CSF)-mobilized, T-cell-depleted, CD34+-selected allogeneic PBSC transplantation on day 0.
After completion of study treatment, patients are followed periodically for at least 1 year.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin Cancer Center
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Midwest Children's Cancer Center at Children's Hospital of Wisconsin
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Primary acute myeloid leukemia (AML)
- First complete remission (CR) with high risk features as defined by: failure to achieve remission by day 21 after induction chemotherapy, or the presence of chromosomal abnormalities involving any of the following: -5/de (5q), -7/del(7q), inversion 3q, abnormalities of 11q23, 20q, 21q, del(9q), translocation 6;9, translocation 9;22, abnormalities of 17p, or complex karyotype with > or = 3 abnormalities. Complete remission is defined as < 5% blasts in the marrow.
- Second CR or subsequent in remission
- Refractory or relapsed disease with absolute peripheral blood blasts < 2000/mcL
- Secondary AML in remission or relapse
Chronic myelogenous leukemia (CML) in accelerated or blast phase
Accelerated phase is defined by any one of the following:
- Blasts 10% to 19% of peripheral blood white cells or bone marrow cells
- Peripheral blood basophils at least 20%
- Persistent thrombocytopenia (<100 x 10^9/L) unrelated to therapy, or persistent thrombocytosis (>1000 x 10^9/L) unresponsive to therapy
- Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy
- Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase CML)
- Resistance to tyrosine kinase inhibitors (imatinib or other) defined as no complete cytogenetic response even if the above criteria are not met.
Blast phase is defined by either of the following:
- Blasts 20% or more of peripheral blood white cells or bone marrow cells
- Extramedullary blast proliferation
- Large foci or clusters of blasts in bone marrow biopsy
- Primary myelodysplastic syndrome (MDS) with an IPSS score >1
- Secondary MDS with any international prostate symptom score (IPSS)
- Age ≤60 years
- Co-Morbidity score 0-2
- At least 35 days following start of preceding leukemia induction therapy
Exclusion Criteria:
- Patients for whom a suitable HLA genotypically identical sibling or fully matched HLA-A, -B, -C, and -DRB1 unrelated donor is available.
- Patients greater than 60 years of age.
- Hypersensitivity to thymoglobulin.
- Symptomatic uncontrolled coronary artery disease or congestive heart failure.
- Hepatic disease with transaminases or bilirubin > 2 times upper limit of normal (ULN) except for isolated hyperbilirubinemia attributed to Gilbert's syndrome.
- Severe hypoxemia with room air - Partial Pressure of Oxygen in Arterial Blood - (PAO2) < 70, supplemental oxygen-dependence, or carbon monoxide diffusing capacity (DLCO) < 50% predicted.
- Impaired renal function with creatinine > 2 times upper limit of normal (ULN) or creatinine clearance measured by 24-hour urine collection < 50% normal for age, gender, and weight.
- Patients with central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy.
- Patients who are human immunodeficiency virus (HIV) seropositive.
- Patients who are pregnant or breast-feeding.
- Patients with active infections that are untreated, or failing to respond to appropriate therapy.
- Karnofsky performance status < 50%.
- Prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplant.
- Inability to provide informed consent.
- Co-morbidity score >2
- Less than 35 days from start of previous leukemia induction therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Natural Killer Cell Kir Epitope
|
Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2.
The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
Andre navne:
Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
Andre navne:
Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
Peripheral Blood Stem Cell (PBSC) Infusion.
All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal.
PBSC is infused via a central venous catheter using blood infusion tubing.
Andre navne:
The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence of Disease-free Survival
Tidsramme: 1 Year
|
Number of patients alive and without disease at 1 year after transplant.
|
1 Year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence of Disease Relapse
Tidsramme: 1 Year
|
Number of patients with disease at 1 year.
|
1 Year
|
Incidence of Grade II-IV Acute Graft-vs-host Disease (GVHD)
Tidsramme: Day 100
|
Number of patients with grade II-IV acute graft-versus-host disease at Day 100 post transplant.
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Grade I=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening.
|
Day 100
|
Incidence of Chronic Graft-versus-host Disease (GVHD)
Tidsramme: 1 Year
|
Number of patients with chronic graft-versus-host disease at 1 year post transplant.
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Grade I=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening.
Chronic GVHD is an extension of acute GVHD.
|
1 Year
|
Incidence of Graft Failure
Tidsramme: Day 100
|
Number of patients with graft failure is defined by lack of neutrophil engraftment by 100 days after transplant in patients surviving a minimum of 14 days.
|
Day 100
|
Transplant-related Mortality
Tidsramme: 1 Year
|
Number of patients with treatment related death at 1 year post transplant.
|
1 Year
|
Overall Survival
Tidsramme: 1 Year
|
Number of patients who were deceased at 1 year post transplant.
|
1 Year
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- de novo myelodysplastiske syndromer
- tidligere behandlede myelodysplastiske syndromer
- sekundære myelodysplastiske syndromer
- akut myeloid leukæmi hos voksne med 11q23 (MLL) abnormiteter
- akut myeloid leukæmi hos voksne med inv(16)(p13;q22)
- akut myeloid leukæmi hos voksne med t(15;17)(q22;q12)
- akut myeloid leukæmi hos voksne med t(16;16)(p13;q22)
- akut myeloid leukæmi hos voksne med t(8;21)(q22;q22)
- sekundær akut myeloid leukæmi
- akut myeloid leukæmi i barndommen i remission
- kronisk myelogen leukæmi i barndommen
- tilbagevendende akut myeloid leukæmi hos voksne
- akut myeloid leukæmi hos voksne i remission
- blastisk fase kronisk myelogen leukæmi
- recidiverende kronisk myelogen leukæmi
- accelereret fase kronisk myelogen leukæmi
- tilbagevendende akut myeloid leukæmi i barndommen
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer efter histologisk type
- Neoplasmer
- Sygdom
- Knoglemarvssygdomme
- Hæmatologiske sygdomme
- Forstadier til kræft
- Syndrom
- Myelodysplastiske syndromer
- Leukæmi
- Præleukæmi
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Fludarabin
- Fludarabin phosphat
- Thiotepa
- Antimfocyt serum
Andre undersøgelses-id-numre
- 2004UC035
- UMN-MT2004-04 (Anden identifikator: Blood and Marrow Transplantation Program)
- UMN-0405M59662 (Anden identifikator: IRB, University of Minnesota)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Myelodysplastiske syndromer
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Riphah International UniversityAfsluttet
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
-
University of CalgaryUkendtNefrotisk syndrom hos børn | Nefrotisk syndrom, minimal ændring | Nefrotisk syndrom, idiopatiskCanada
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutation | Shashi-Pena syndrom | ASXL2-genmutation | Bainbridge-Ropers syndrom | ASXL3 genmutationForenede Stater
Kliniske forsøg med anti-thymocyte globulin
-
Wright State UniversitySanofi; University of Nebraska; University of Arizona; The Methodist Hospital... og andre samarbejdspartnereAfsluttetSlutstadie nyresygdom | NyresvigtForenede Stater
-
University of CincinnatiGenzyme, a Sanofi CompanyAfsluttetAfstødning af nyretransplantation | Transplantationer og implantaterForenede Stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AfsluttetMyelom og plasmacelle-neoplasmaForenede Stater
-
Genzyme, a Sanofi CompanyAfsluttetMyelodysplastiske syndromerForenede Stater, Canada
-
M.D. Anderson Cancer CenterAfsluttetKronisk lymfatisk leukæmi | Myelodysplastisk syndrom | Akut myelogen leukæmiForenede Stater
-
Hospital de Clinicas de Porto AlegreAfsluttetImmunsuppression | Nyretransplantation; KomplikationerBrasilien
-
European Institute of OncologyIstituto Clinico HumanitasAfsluttet
-
Genzyme, a Sanofi CompanyAfsluttetMyelodysplastisk syndrom (MDS)Tyskland, Det Forenede Kongerige, Frankrig, Holland
-
Swedish Medical CenterGenzyme, a Sanofi CompanyAfsluttetImmunsuppression | NyretransplantationForenede Stater
-
University of California, Los AngelesGenzyme, a Sanofi CompanyTrukket tilbageHjertetransplantation | Iskæmisk reperfusionsskadeForenede Stater